FDA
-
-
-
-
-
-
-
Lunai Bioworks, Inc. Issues Letter to Shareholders
-
-
-
-
-
-
-
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
-
-
-
-
-
-
-
Supernus Announces Fourth Quarter and Full Year 2024 Financial Results
-
-
-
-
-
-
-
Supernus Announces Label Update for Non-Stimulant ADHD Treatment, Qelbree®, Including New Pharmacodynamic Data and Information for Breastfeeding Women
-
-
-
-
-
-
-
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
-
-
-
-
-
-
-
Supernus Provides Regulatory Update for SPN-830
-
-
-
-
-
-
-
Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey
-
322,084 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

